Scaleup programmes

Back to programmes

Programme

Babraham Research Campus

Infrastructure

Impact for scaleups

2,000+

Size of the community

£5bn+

Market value of campus companies

c.£500m

commercial investment raised in 2021/22

£286m

GVA impact of the Campus on UK economy

3 months

Average time saving for companies raising funds

Key sectors

Life Sciences & Biotech

Babraham Research Campus is a highly connected, sustainable and dynamic ecosystem. It is focused on creating new discoveries, therapeutics, jobs and growth to support the UK economy. It aims to be a leading sustainable ecosystem and one of the best places in the world for discovery bioscience research and innovation. It brings together world leading bioscience research and business to accelerate scientific discovery and to help build and scale businesses. 

Scaleups are part of a supportive campus infrastructure and have access to laboratories and offices via short-term leases, giving them the opportunity to grow into larger spaces when they evolve. The Accelerate@Babraham bioincubator programme provides additional support for early-stage life science scaleups and is recognised by Labiotech as one of the top 25 such incubators in Europe. The five-month programme includes tailored scientific, business, and technical support, free lab space, access to the Cambridge Cluster network, investor introductions and access to £10k of non-diluted funding. To join the programme, companies undergo an annual competitive application and pitching process. Up to five early-stage ventures are selected  as part of each cohort to experience life as part of the Babraham Research Campus.

Additionally for scaleups seeking investment, the annual Babraham Investor Conference, last held in September 2023, provides a collaborative and information environment that brings together hundreds of investors, companies and industry leaders in order to facilitate access to venture capital investment. 

In October 2023, the Campus announced that, in partnership with BioMed Realty, it will be opening a new 34,000 square feet purpose-built facility in order to address the growing demand for lab space in Cambridge. Key tenants moving into expansive scale-up labs within the new building, scheduled to open in early 2024, include scaling businesses Xap Therapeutics and Mosaic Therapeutics.

In a 2020 review of the Campus’ economic impact, Campus-based companies estimated that they had on average accelerated their fundraising by three months and increased the amount of funds raised by 10%.  It is also estimated that employee numbers of resident firms are around 20% larger than they otherwise may have been due to the Campus location. The total market value of the largest 14 companies on site was calculated to be £5bn. 

Babraham Research Campus website